INNATE PHARMA SA (IPHA) Social Stream



INNATE PHARMA SA (IPHA): $2.38

0.06 (-2.46%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add IPHA to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#103 of 471

in industry

INNATE PHARMA SA (IPHA) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering INNATE PHARMA SA.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-03-25 2 $11.5 $9 $10.25 $2.79 267.38%
2022-05-12 2 $11.5 $11 $11.25 $2.79 303.23%
2022-08-02 2 $11.5 $10 $10.75 $2.79 285.3%
2023-03-24 3 $12 $9 $10.833 $2.79 288.28%
2023-06-02 3 $12 $10 $11.166 $2.79 300.22%
2023-09-18 3 $11.5 $10 $10.75 $2.79 285.3%
2023-11-14 3 $11.5 $8 $9.833 $2.79 252.44%

The Trend in the Analyst Price Target


Over the past 20 months, IPHA's average price target has gone down $0.42.

IPHA reports an average of 271.74% for its upside potential over the past 34 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-24 3 12.0 9 10.833 2.88 276.15%
2023-04-10 3 12.0 10 11.166 3.19 250.03%
2023-09-18 3 11.5 8 9.833 2.75 257.56%
2023-09-28 3 11.5 8 9.833 2.64 272.46%
2023-11-14 3 11.5 8 9.833 2.58 281.12%

IPHA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 3 0 0 0 0 3

The Trend in the Broker Recommendations


IPHA's average broker recommendation rating improved by 0 over the prior 23 months.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In terms of how INNATE PHARMA SA fares relative to all US stocks, note that its number of analysts covering the stock is higher than 37.86% of that group.
  • To contextualize these metrics, consider that out of all US stocks, INNATE PHARMA SA's upside potential (average analyst target price relative to current price) is greater than 630.46% of them.
  • In the context of Pharmaceutical Products stocks, INNATE PHARMA SA's variance in analysts' estimates is lower than 27.85% of them.
  • In terms of how INNATE PHARMA SA fares relative to Healthcare stocks, note that its average analyst price target is greater than 130.98% of that group.

In the Pharmaceutical Products industry, DTIL, GNFT, and INMB are the three stocks most similar to INNATE PHARMA SA regarding the price target and analyst recommendation information presented here.

Is IPHA a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!